Literature DB >> 7529476

The interferons: biological effects, mechanisms of action, and use in multiple sclerosis.

B Weinstock-Guttman1, R M Ransohoff, R P Kinkel, R A Rudick.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1995        PMID： 7529476     DOI： 10.1002/ana.410370105

Source DB:  PubMed          Journal:  Ann Neurol        ISSN： 0364-5134            Impact factor:   10.422


× No keyword cloud information.
  34 in total

Review 1.  Therapeutic strategies in multiple sclerosis. I. Immunotherapy.

Authors:  R Hohlfeld
Journal:  Philos Trans R Soc Lond B Biol Sci       Date:  1999-10-29       Impact factor: 6.237

Review 2.  Comparative assessment of immunomodulating therapies for relapsing-remitting multiple sclerosis.

Authors:  Omar Khan; Rana Zabad; Christina Caon; Marina Zvartau-Hind; Alexandros Tselis; Robert Lisak
Journal:  CNS Drugs       Date:  2002       Impact factor: 5.749

3.  Interferon-gamma induced increases in intracellular calcium in T lymphocytes from patients with multiple sclerosis precede clinical exacerbations and detection of active lesions on MRI.

Authors:  G Martino; M Filippi; V Martinelli; E Brambilla; C Gobbi; G Comi; L M Grimaldi
Journal:  J Neurol Neurosurg Psychiatry       Date:  1997-09       Impact factor: 10.154

4.  Interferon-gamma activated calcium influx in peripheral blood lymphocytes from patients with primary and secondary progressive multiple sclerosis.

Authors:  G Martino; E Brambilla; M Filippi; V Martinelli; B Colombo; M Rodegher; G Comi; L M Grimaldi
Journal:  J Neurol Neurosurg Psychiatry       Date:  1996-11       Impact factor: 10.154

5.  Psychometric properties of the Hamilton Depression Rating Scale in multiple sclerosis.

Authors:  Simona Raimo; Luigi Trojano; Daniele Spitaleri; Vittorio Petretta; Dario Grossi; Gabriella Santangelo
Journal:  Qual Life Res       Date:  2015-02-11       Impact factor: 4.147

6.  Expression and functional significance of SOCS-1 and SOCS-3 in astrocytes.

Authors:  Hongwei Qin; Sandrine A Niyongere; Sun Jung Lee; Brandi J Baker; Etty N Benveniste
Journal:  J Immunol       Date:  2008-09-01       Impact factor: 5.422

7.  Structural and functional differences between glycosylated and non-glycosylated forms of human interferon-beta (IFN-beta).

Authors:  L Runkel; W Meier; R B Pepinsky; M Karpusas; A Whitty; K Kimball; M Brickelmaier; C Muldowney; W Jones; S E Goelz
Journal:  Pharm Res       Date:  1998-04       Impact factor: 4.200

Review 8.  Magnetic resonance imaging of multiple sclerosis lesions. Measuring outcome in treatment trials.

Authors:  J H Simon
Journal:  West J Med       Date:  1996-06

9.  Interferon (IFN) beta acts downstream of IFN-gamma-induced class II transactivator messenger RNA accumulation to block major histocompatibility complex class II gene expression and requires the 48-kD DNA-binding protein, ISGF3-gamma.

Authors:  H T Lu; J L Riley; G T Babcock; M Huston; G R Stark; J M Boss; R M Ransohoff
Journal:  J Exp Med       Date:  1995-11-01       Impact factor: 14.307

10.  Myelin basic protein-primed T cells induce nitric oxide synthase in microglial cells. Implications for multiple sclerosis.

Authors:  Subhajit Dasgupta; Malabendu Jana; Xiaojuan Liu; Kalipada Pahan
Journal:  J Biol Chem       Date:  2002-08-09       Impact factor: 5.157
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.